Proceedings: Immunotherapy of malignant disease: the use of viable sensitized lymphocytes or transfer factor prepared from sensitized lymphocytes.
D000230:Adenocarcinoma / Q000628:therapy; D001789:Blood Group Antigens; D001803:Blood Transfusion; D002478:Cells, Cultured; D003110:Colonic Neoplasms / Q000628:therapy; D003601:Cytotoxicity Tests, Immunologic; D005069:Evaluation Studies as Topic; D006801:Humans; D007112:Immunity, Maternally-Acquired; D007167:Immunotherapy; D008213:Lymphocyte Activation; D017710:Lymphocyte Transfusion; D008214:Lymphocytes / Q000276:immunology; D008545:Melanoma / Q000628:therapy; D009368:Neoplasm Transplantation; D009369:Neoplasms / Q000628:therapy*; D012516:Osteosarcoma / Q000628:therapy; D013584:Sarcoma, Synovial / Q000628:therapy; D012878:Skin Neoplasms / Q000628:therapy; D014184:Transplantation, Homologous
D001789:Blood Group Antigens